Repurposed Drug Database


Phentolamine

Original Indication
Dermal Necrosis (hypertension).
New Indication
Autism.

Paclitaxel

Original Indication
Cancer.
New Indication
Restenosis.

Protein C concentrate

Original Indication
Ceprotin is indicated for patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
New Indication
For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.

Procarbazine hydrochloride

Original Indication
Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen.
New Indication
Treatment of malignant glioma.

Pazopanib

Original Indication
Treatment of patients with advanced renal cell carcinoma.
New Indication
Treatment of soft tissue sarcomas.

Peginterferon alfa-2a

Original Indication
Alone or in combination with COPEGUS, it is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. It's also indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation.
New Indication
Treatment of chronic myelogenous leukemia.

Peginterferon alfa-2b

Original Indication
1. Combination therapy with REBETOL (ribavirin): Chronic Hepatitis C (CHC) in patients 3 years with compensated liver disease. 2. Monotherapy: CHC in patients ( 18 years) with compensated liver disease previously untreated with interferon alpha.
New Indication
Treatment of malignant melanoma stages IIb through IV.

Pentosan polysulfate sodium

Original Indication
Relief of bladder pain or discomfort associated with interstitial cystitis.
New Indication
Treatment of sickle cell disease.

Polyphenon E

Original Indication
Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
New Indication
Treatment of chronic lymphocytic leukemia.

Pramipexole

Original Indication
1. the treatment of the signs and symptoms of idiopathic Parkinson's disease. 2. the treatment of moderate-to-severe primary Restless Legs Syndrome.
New Indication
Treatment of Tourette's syndrome in pediatric patients.

Praziquantel

Original Indication
Treatment of infections due to: all species of schistosoma (e.g. Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/ Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated).
New Indication
Treatment of neurocysticercosis.

Progesterone

Original Indication
Prometrium (progesterone) capsule is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.
New Indication
Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.

Propranolol

Original Indication
1. Management of hypertension. 2. Decrease angina frequency and increase exercise tolerance in patients with angina pectoris. 3. Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. 4. Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. 5. Prophylaxis of common migraine headache. 6. Management of familial or hereditary essential tremor. 7. Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. 8. As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors.
New Indication
Treatment of proliferating infantile hemangiomas requiring systemic therapy.

Protirelin

Original Indication
1. As an adjunctive agent in the diagnostic assessment of thyroid function. 2. As an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. 3. Adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism.
New Indication
Prevention of infant respiratory distress syndrome associated with prematurity.

Pentostatin

Original Indication
Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.
New Indication
Treatment of patients with chronic lymphocytic leukemia.

Porfimer sodium

Original Indication
1. Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy. 2. Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). 3. Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated. 4. Ablation of high-grade dysplasia in Barrett s esophagus patients who do not undergo esophagectomy.
New Indication
For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.

Pralatrexate

Original Indication
Treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
New Indication
Treatment of diffuse large B-cell lymphoma.

Primaquine phosphate

Original Indication
For the radical cure (prevention of relapse) of vivax malaria.
New Indication
For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.

Peginterferon alfa-2a

Original Indication
1. PEGASYS, peginterferon alfa-2a, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g, antiretroviral therapy not required or receiving stable antiretroviral therapy).2.PEGASYS is indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation.
New Indication
Treatment of chronic myelogenous leukemia.

Peginterferon alfa-2b

Original Indication
PegIntron is an antiviral indicated for: 1. Combination therapy with REBETOL (ribavirin): Chronic Hepatitis C (CHC) in patients 3 years with compensated liver disease. 2. Monotherapy: CHC in patients ( 18 years) with compensated liver disease previously untreated with interferon alpha.
New Indication
Treatment of chronic delta hepatitis.

Paclitaxel

Original Indication
Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
New Indication
Treatment of pancreatic cancer.

Paclitaxel aqueous gel

Original Indication
Paclitaxel is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
New Indication
Treatment of esophageal cancer.

Paclitaxel protein-bound particles for injection suspension

Original Indication
ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
New Indication
Treatment of stage IIb to IV melanoma.

Load More